Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2003 | 03-2003 | 12-2002 | 09-2002 | 06-2002 | |
| Sales | 6,203,000 | 5,721,000 | 5,268,000 | 5,373,000 | 5,193,000 |
| Cost of Goods | 1,423,000 | 1,363,000 | 1,680,860 | 1,306,000 | 1,229,000 |
| Gross Profit | 4,780,000 | 4,358,000 | 5,772,880 | 4,067,000 | 3,964,000 |
| Operating Expenses | 3,317,000 | 3,007,000 | 3,980,040 | 2,747,000 | 2,632,000 |
| Operating Income | 1,463,000 | 1,351,000 | -392,040 | 1,320,000 | 1,332,000 |
| Other Income | 128,000 | -66,000 | 2,303,710 | 123,000 | 205,000 |
| Pre-tax Income | 1,591,000 | 1,285,000 | 1,911,670 | 1,443,000 | 1,537,000 |
| Income Tax | 270,000 | 219,000 | 320,430 | 245,000 | 246,000 |
| Net Income Continuous | 1,321,000 | 1,066,000 | 1,103,000 | 1,198,000 | 1,291,000 |
| Minority Interests | 5,000 | 3,000 | -2,000 | 10,000 | 5,000 |
| Net Income | $1,316,000 | $1,063,000 | $1,103,000 | $1,188,000 | $1,286,000 |
| EPS Basic Total Ops | 0.53 | 0.43 | 0.45 | 0.48 | 0.50 |
| EPS Basic Continuous Ops | 0.53 | 0.43 | 0.45 | 0.48 | 0.51 |
| EPS Diluted Total Ops | 0.52 | 0.42 | 0.45 | 0.47 | 0.48 |
| EPS Diluted Continuous Ops | 0.53 | 0.43 | 0.45 | 0.48 | 0.51 |
| EBITDA(a) | $1,752,000 | $1,655,000 | $-423,040 | $1,562,000 | $1,592,000 |